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ABSTRACT
Objectives: To compare efficacy of oxybutynin and tolterodine in managing Detrusor Overactivity (DO) in Pakistani patients
with different upper motor neuron lesions. Methods: A randomized controlled trial was carried out at Armed Forces Institute
of Rehabilitation Medicine, Rawalpindi from January to August 2015 including individuals with a diagnosis of DO as a result
of upper motor neuron lesions. Maximal detrusor pressure (MDP) and maximal cystometric capacity (MCC) were measured
at baseline and at four months post-treatment. Group-A was treated with tolterodine and group-B with oxybutynin. Results:
A total of 60 individuals (mean age: 43.9 ± 15 years) were included. Majority (83.3%) were male and had spinal cord injury
as the commonest etiology (56.7%). Group-A had a mean pre-treatment MCC of 188.3 ± 48.2 ml, and a mean
post-treatment MCC of 281.5 ± 49.1 ml (p< 0.001). The mean pre-treatment MDP was 83.6 ± 9.5 cm of H2O, and the
mean post-treatment value was 40.9 ± 10.2 cm of H2O (p< 0.001). Group-B had a mean pre-treatment MCC of 209.8
± 60.5 ml, and mean post-treatment MCC of 308.7 ± 65 ml (p< 0.001). The mean pre-treatment MDP was 80.7 ± 10.6
cm of H2O, and the mean post-treatment value was 40.7 ± 10.1 cm of H2O (p< 0.001). The difference in mean reduction
in MCC and MDP produced by tolterodine and oxybutynin was statistically insignificant. Conclusions: Both oxybutynin and
tolterodine showed similar efficacy in the treatment of DO based on measurable urodynamic outcomes.
Key Words: Detrusor overactivity, oxybutynin, Pakistan, tolterodine, upper motor neuron lesions
BACKGROUND

upper motor neuron lesions. Bladder management in
UMN lesions focuses on carefully diagnosing the
underlying bladder disorder and its targeted treatment.
The treatment of DO can be undertaken on clinical
grounds but it is beneficial to quantify the defect on
objective parameters like the urodynamic study because it
helps in monitoring the response to treatment and in
gathering data for future follow up. The aim of bladder
management in DO is to improve the bladder capacity and
decrease the detrusor contractions in order to enable
clean intermittent catheterization (CIC) by the patient.
This can be achieved by various modalities including
pharmacotherapy as well as surgical options.
Pharmacotherapy is the most commonly used first line
treatment because of non-invasiveness, efficacy and ease
of use. The drug options include anticholinergics/
antimuscarinics, tricyclics, intravesical instillation of
capsaicin or lignocaine and botulinum injections to the
detrusor muscle. Anti-muscarinic agents are the
backbone of pharmacological treatment for DO.[2,3] These
agents are used to abolish detrusor contractions in order

Upper motor neuron (UMN) injury can result from a large
number of conditions which are quite common in the
population. The conditions which lead to UMN lesions
include cerebrovascular accidents, traumatic brain injury,
Parkinson’s disease, multiple sclerosis and suprasacral
spinal cord injury, etc. Detrusor overactivity (DO) is one of
the deleterious consequences of many upper motor
neuron lesions. DO is underdiagnosed and commonly
untreated. The problem is further compounded by
complications like vesicoureteric reflux, hydronephrosis,
nephropathy, urinary tract infections, urolithiasis, chronic
kidney disease and even malignancy.[1] This deteriorates
the quality of life of the patient not only due to medical
complications but also because of the ensuing depression
and social stigmatization thus creating hindrance in early
achievement of rehabilitation goals. At the same time, the
complications put an extra burden on the healthcare
system. This is the reason why treatment of bladder
dysfunction is an important pillar in the management of
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to permit voiding by CIC. Antimuscarinics have been
considered the gold standard of treatment for many
decades but are well-known for their side effects
presenting as dry mouth, constipation and tachycardia.
Oxybutynin is the most commonly used drug in this class
and can be used orally and/ or intravesically.[4] Tolterodine
is another commonly used antimuscarinic agent and has
lesser incidence of side effects than oxybutynin in usual
doses.[5] Recently, many newer drugs with better
tolerability have been added to the arsenal against DO.[6]
In Pakistan, most patients are unable to afford the newer
agents. The mainstay of treatment for DO remains either
oxybutynin or tolterodine, out of which oxybutynin is the
cheaper choice.[7] International studies have proved that
both these drugs have a comparable efficacy in dealing
with DO.[8,9,10] No study has been conducted in our
indigenous population to address this issue so far, using
objective and measurable outcomes like improvement in
urodynamic parameters. This issue has been addressed in
the present study which aims to gather reproducible data
on the subject.

pressure. It was measured in cm of H2O. MCC is the
volume at which the patient feels that he/she can no
longer delay micturition. It was measured in ml. The
patients were consecutively divided into two study groups
i.e. Group A and B. Group A was treated with oral
tolterodine (Detrusitol, Pfizer Laboratories, Karachi,
Pakistan) 2 mg twelve hourly [11] and group B received oral
oxybutynin (Taivor, Raazee Therapeutics, Lahore,
Pakistan) 3 mg eight hourly.[12] The urodynamic
parameters assessed at baseline were repeated after four
weeks. The data were endorsed for each patient in a
written proforma. The data were analyzed with the help of
statistical program Statistical Package for Social sciences
(SPSS) version 19.0 (IBM Corp., Armonk, NY, USA).
Descriptive statistics were calculated for both qualitative
and quantitative variables. For qualitative variables like
gender and primary diagnosis of UMN lesion, frequencies
and percentages were calculated and for quantitative
variables like age, MDP and MCC, means and standard
deviations were calculated. Paired-samples t-test was
applied to statistically analyze the effect of both
therapeutic modalities in either study groups. The mean
reduction in MCC and MDP between two groups were
compared using independent-samples t-test. A p-value <
0.05 was considered significant.

MATERIALS AND METHODS
It was a single blinded randomized controlled trial carried
out at Armed Forces Institute of Rehabilitation Medicine,
Rawalpindi from January 2015 to August 2015. We
included individuals belonging to both genders fitting in
the age group of 18-60 years with a diagnosis of DO as a
result of upper motor neuron lesions. We had chosen the
above mentioned age limit to lessen the influence of
confounding factors in geriatric and pediatric population.
Above 60 years, the females are likely to have stress
incontinence and males are prone to develop lower
urinary tract symptoms due to prostatic disease. Likewise,
the urodynamic parameters in the pediatric population are
different than adults. Patients having conditions other
than DO that might have led to urinary incontinence or
urgency e.g. urinary tract infection, prostatic hypertrophy
or utero-vaginal prolapse were excluded from the study.
Smokers and women who were pregnant or breast feeding
their children were also placed in the exclusion group.
After approval from the hospital ethics committee,
prospective candidates for enrollment were evaluated
thoroughly to meet the inclusion criteria. Patient’s
informed consent for participation was taken after
explaining the objectives and benefits of the study. The
patients who were enrolled underwent baseline
urodynamic studies using PICO SMART Urodynamics
System (PICO SMART, Menfis Division, MEDICA S.p.A.,
Bologna, Italy) to quantify maximal detrusor pressure
(MDP) and maximal cystometric capacity (MCC). MDP is
the pressure created by bladder wall forces. It is a
component of intravesical pressure and is calculated by
subtracting abdominal pressure from intravesical
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RESULTS
A total of 60 patients suffering from UMN pathology
attributed to various clinical conditions, regardless of age
and gender, were included in the study. Fifty patients
(83.3%) were male and ten (16.7%) were female. Mean
age of the patients was 43.9 ± 15 years with a range of
13-72 years. The cause of upper motor neuron lesion was
spinal cord injury in 56.7% (n=34) of the patients
followed by cerebrovascular accident (23.3%,n=14),
Parkinson’s disease (5%,n=3), cerebral palsy (5%, n=3),
spinal tuberculosis (5%,n=3), acquired brain injury
(3.3%,n=2) and spinal cord tumors (1.7%, n=1)
(Figure-1). Mean pre-treatment MCC was 199.1 ± 55.5
ml, and the mean post-treatment MCC was 295.1 ± 59
ml. Mean pretreatment MDP was 82.1 ± 10.2 cm of
H2O, and the mean post-treatment value was 40.8 ±
10.1 cm of H2O.

Figure-1: Figure showing relative percentages of different
primary etiologies for upper motor neuron lesion in the sample

02

VOL. 10 (4) OCT - DEC 2015

tried to find out the difference in efficacy of commonly
available antimuscarinic agents available in Pakistan while
targeting Pakistani population. We found that, though
both tolterodine and oxybutynin were effective in reducing
MDP and MCC, there was no significant difference in the
magnitude of effect produced by both drugs. Madhuvrata
P et al. embarked upon a study to compare the two drugs
in question in our study. They concentrated on bladder
leakage episodes in 24 hours and patients’ perception of
improvement in quality of life. Their results were similar to
ours in that both the drugs caused significant but
comparable improvements in subjective parameters. [13]
In a double blind, multicenter study carried out to
compare relative effectiveness of tolterodine (4 mg daily),
transdermal oxybutynin and placebo [14], no significant
differences were seen in the outcome parameters
between the two drugs. However, both were significantly
more effective than placebo in reducing incontinence
episodes (75% vs 50%) both P < 0.05 vs placebo. In the
Overactive Bladder: Performance of Extended Release
Agents (OPERA) trial, a comparison was made between
extended release oxybutynin (OXY-ER, 10 mg) and
tolterodine(TOL-ER, 4 mg). With both these drugs,
comparable results were obtained regarding control of
incontinence. However oxybutynin was found to had a
greater impact on the total micturition frequency per week
(28.4 vs 25.2; P = 0.003) as well as overall dry rate
(23% vs 16.8%; P = 0.03).[15] Many studies have
established a superiority of tolterodine over oxybutynin in
side effects’ profile. This has led to more compliance with
tolterodine therapy and fewer dropouts. The side effect
profile was found to be much better especially with
dryness of mouth and cognitive impairment. This is
because tolterodine has been documented to have 8-fold
less affinity to the muscarinic receptors at the parotid
gland in radioligand binding.[16, 17, 18] We under took this
study because of the high burden of this disorder in the
outdoor and as well as the indoor in our Institute. We
searched but did not find a single indigenous study on this
topic using urodynamic parameters as the gauge to
determine efficacy. Our study was carried out to try to
address this issue. We, the physicians in the third world,
more than our counterparts in the developed world, have
to balance the efficacy of a drug against its cost.
Oxybutynin is a relatively cheaper drug and therefore is
more easily available to our patients. Based on the
volume of literature in favor of comparable effectiveness
of oxybutynin and tolterodine, we chose the null
hypothesis to be the expected outcome on urodynamic
parameters. As hypothesized, our results revealed no
significant difference in the relative effectiveness of these
two drugs. Therefore our study validates the results of
previous studies as mentioned above. This has helped us
to be more confident in prescribing this drug without
feeling the guilt of withholding a potentially better drug

Twenty-six males and 4 females (n=30) were in group A.
Rest of the 24 males and 6 females (n=30), were in
group B. Group A had a mean pre-treatment MCC of
188.3 ± 48.2 ml, and a mean post-treatment MCC of
281.5 ± 49.1 ml. (Table-1) The mean pretreatment MDP
was 83.6 ± 9.5 cm of H2O, and the mean
post-treatment value was 40.9 ± 10.2 cm of H2O. Group
B had a mean pre-treatment MCC of 209.8 ± 60.5 ml,
and mean post-treatment MCC of 308.7 ± 65 ml. The
mean pretreatment MDP was 80.7 ± 10.6 cm of H2O,
and the mean post-treatment value was 40.7 ± 10.1 cm
of H2O.(Table-1)
Pretreatment
mean MCC*

Posttreatment
mean MCC

Tolterodine

188.3 ± 48.2

MCC of
281.5 ± 49.1

Oxybutynin

209.8 ± 60.5

308.7 ± 65

Mean
reduction in
MCC with Pvalue

93.2 ± 18.6,
p < 0.001
98.9 ± 26.7,
p < 0.001

Pretreatment
mean MDP*

Posttreatment
mean MDP

Mean
reduction in
MDP with Pvalue

83.6 ± 9.5

40.9 ± 10.2

42.7 ± 3.9, p
< 0.001

80.7 ± 10.6

40.7 ± 10.1

40 ± 10.6,
p < 0.001

*MCC: Maximalcystometric capacity
**MDP:Maximaldetrusor pressure
Table-1:Table showing comparison of the effect of oxybutynin and tolterodineonmaximal cystometric capacity and
maximaldetrusor pressure

Each drug significantly reduced MCC and MDP in its group
(p< 0.001, p< 0.001, p< 0.001 and p< 0.001
respectively). The mean reduction in MCC produced by
tolterodine (93.2 ± 18.6) was less than that produced by
oxybutynin (98.9 ± 26.7) but did not satisfy the statistical
tests for significance (p=0.179). Similarly, the mean
reduction in MDP produced by tolterodine (42.7 ± 3.9)
was more than that produced by oxybutynin (40 ± 10.6)
but could not reach a statistically significant value (p=
0.068).
*MCC: maximal cystometric capacity
**MDP: Maximal detrusor pressure
Table-1: Table showing comparison of the effect of
oxybutynin and tolterodine on maximal cystometric capacity
and maximal detrusor pressure

DISCUSSION
DO is commonly seen in patients with UMN lesions as
evidenced by various community and hospital based
surveys. The complications relating to this disorder are
also quite frequent in this population which can be
averted to some extent by the use of appropriate
modalities. For these patients the care of the bladder is an
essential component of any rehabilitation program. In
practice, balancing between efficacy and side effects is a
challenge. Moreover, cost effectiveness is a major
determinant in choosing the appropriate drugs especially
in poor countries. A lot of studies have been conducted to
determine the safety and efficacy of antimuscarinic
agents that are the cornerstone of treatment in patients
with both neurogenic and non-neurogenic DO. We also
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because of financial constraints. The study had a
shortcoming. A long term follow up was required to
determine the relative frequency of long term treatment
failures and dropouts amongst the two groups which could
not be carried out properly because of time limitation.

9.

CONCLUSIONS

10.

Both oxybutynin and tolterodine showed similar efficacy in
the treatment of DO based on measurable urodynamic
outcomes. The improvements in the urodynamic
parameters were significant with both these drugs, so
their regular use in appropriate patients is justified. Our
study was the first of its kind in Pakistan. As mentioned
earlier, the database available on DO is not of a very high
quality, therefore there is a need to continue research on
this subject to further elucidate the differences in
response to treatment, if any, amongst the various causes
of neurogenic bladder.

11.

12.
13.
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